What is the appropriate dose of MiraLAX (polyethylene glycol 3350) for a 19‑month‑old child weighing approximately 24 lb (≈11 kg) with constipation, and how should it be administered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

MiraLAX Dosing for a 19-Month-Old with Constipation

For a 19-month-old child weighing 24 lb (11 kg) with functional constipation, start polyethylene glycol 3350 (MiraLAX) at 0.8 g/kg/day (approximately 8.8 grams daily), mixed into any beverage and given once daily, with dose adjustments based on response to achieve 1-2 soft, comfortable bowel movements per day.

Recommended Dosing Strategy

Initial Dose

  • Starting dose: 0.8 g/kg/day for maintenance therapy of functional constipation 1, 2, 3
  • For an 11 kg child, this equals approximately 8.8 grams daily
  • This is roughly half of the adult 17-gram capful that comes with MiraLAX 4

Administration

  • Mix the powder completely into 4-8 ounces of any beverage (water, juice, milk) until dissolved 4
  • Give once daily, preferably at the same time each day
  • The powder is grit-free and unflavored, making it easier for toddlers to accept 4

Dose Titration

The dose should be adjusted every 2-3 days based on stool output:

  • Goal: 1-2 soft, painless bowel movements per day 1, 3
  • If insufficient response: Increase by 0.1-0.2 g/kg increments
  • If diarrhea occurs: Decrease the dose; diarrhea typically resolves with dose reduction 1, 2
  • Effective dose range: Studies show most toddlers respond to 0.27-1.42 g/kg/day 1, 3

Evidence Supporting This Approach

Pediatric-Specific Data

The dosing recommendation is based on multiple studies specifically evaluating PEG 3350 in infants and toddlers under 2 years of age:

  • A retrospective study of 75 children under 24 months (mean age 17 months) found that mean effective dose was 0.8 g/kg/day for long-term therapy, with 91% achieving constipation relief 1
  • Another study of 28 infants under 18 months demonstrated a mean effective maintenance dose of 0.78 g/kg/day, with 97.6% success rate 2
  • These doses are consistent with findings in older children, where 0.84 g/kg/day was effective for maintenance 3

Safety Profile in Toddlers

  • PEG 3350 is well-tolerated in this age group with minimal adverse effects 1, 2
  • The most common side effect is transient diarrhea (occurring in approximately 13% of patients), which resolves with dose adjustment 2
  • No clinically significant electrolyte abnormalities have been reported 5
  • No children discontinued therapy due to adverse effects in the toddler studies 1, 2

Important Clinical Considerations

Duration of Therapy

  • Long-term use is safe and often necessary in pediatric functional constipation 6
  • Studies demonstrate safety and efficacy for 6-21 months of continuous use 1, 6
  • Many children require prolonged therapy (mean 18.6 months in one study) without need for dose adjustment despite weight gain 6

When to Seek Medical Attention

Contact a healthcare provider immediately if the child develops:

  • Red flag symptoms: Vomiting, significantly distended abdomen, severe abdominal pain
  • Signs of fecal impaction: No bowel movement after 3-4 days of therapy at adequate doses
  • Persistent symptoms despite appropriate dosing adjustments

Adjunctive Measures

Combine PEG therapy with:

  • Adequate fluid intake throughout the day
  • Dietary modifications: Offer high-fiber foods like pears, prunes, peaches, and oatmeal as mentioned
  • Behavioral interventions: Regular toilet sitting after meals (for older toddlers who are toilet training)

Common Pitfalls to Avoid

  1. Don't use the full adult 17-gram dose unless specifically directed by the pediatrician—this is more than double the appropriate starting dose for this weight 4, 1

  2. Don't discontinue therapy too early—premature withdrawal often leads to relapse. Most children require several months of treatment 6

  3. Don't ignore the need for dose titration—the initial dose is a starting point. Parents should adjust based on stool frequency and consistency to find the optimal individual dose 1, 3

  4. Don't expect immediate results—it may take several days to see full effect, and dose adjustments should be made gradually every 2-3 days 3

Practical Dosing Calculation

For this specific 24 lb (11 kg) child:

  • Starting dose: 0.8 g/kg × 11 kg = 8.8 grams daily
  • Practical measurement: The MiraLAX cap holds 17 grams, so use approximately half a capful (slightly more than half) 4
  • Alternative: Use a kitchen scale to measure 8.8 grams of powder for precision

The information you provided about starting at approximately 4.4 grams appears to be roughly 0.4 g/kg, which is lower than the evidence-based starting dose. While this conservative approach may work for some children, studies specifically in toddlers demonstrate that 0.8 g/kg/day is the mean effective dose and is well-tolerated as a starting point 1, 2, 3.

Related Questions

What is the appropriate dose of polyethylene glycol 3350 (Miralax) for a 3‑year‑old child weighing 32 lb (≈14.5 kg) with constipation?
What is the appropriate dose of polyethylene glycol 3350 (MiraLAX) for a 21‑month‑old child?
What is the appropriate dose of MiraLAX (polyethylene glycol 3350) for a 2‑year‑old child weighing approximately 12–14 kg?
What is the appropriate prescription for polyethylene glycol 3350 for a 14‑year‑old adolescent with a one‑month history of constipation and intermittent abdominal discomfort?
What is the appropriate PEG 3350 (Restoralax) dose for a child weighing 12.2 kg?
Will ceftriaxone (Rocephin) and doxycycline adequately cover Streptococcus pneumoniae?
What are the indications to add methicillin-resistant Staphylococcus aureus (MRSA) coverage in a patient with febrile neutropenia?
What is the appropriate evaluation and management for a patient presenting with neck stiffness (nuchal rigidity) and muscle cramps?
In a patient with heart failure with preserved ejection fraction and stage 3b chronic kidney disease using a bilevel positive airway pressure device, can isolated periods of 5–10 central apneas over a 30‑minute interval be harmful despite an overall nightly apnea‑hypopnea index below 5?
What are the recommended ceftriaxone dosing regimens for adults and children, including special dosing for meningitis and gonococcal infection?
For a 20‑kg child requiring 0.4 g/kg/day of polyethylene glycol 3350, what amount (in teaspoons or tablespoons) should be given each dose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.